Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelial dysfunction in patients with polycythaemia vera.

T Neunteufl1, S Heher, T Stefenelli

  • 1Department of Cardiology, University of Vienna, Vienna, Austria. thomas.neunteufl@univie.ac.at

British Journal of Haematology
|November 13, 2001
PubMed
Summary

Polycythaemia vera (PV) patients exhibit impaired flow-mediated vasodilatation (FMD), indicating pre-clinical arterial disease. This endothelial dysfunction in PV suggests an increased cardiovascular risk, even without overt symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.

ESMO open·2026
Same author

Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer.

Thrombosis research·2026
Same author

The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.

ESMO open·2025
Same author

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Arterial stiffness in acute COVID-19 and potential associations with clinical outcome.

Journal of internal medicine·2021
Same author

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Vascular Biology

Background:

  • Polycythaemia vera (PV) significantly elevates the risk of arterial and venous thromboembolic events.
  • Endothelial dysfunction is a recognized contributor to cardiovascular disease, often seen in patients with traditional risk factors.

Purpose of the Study:

  • To investigate endothelial function, specifically flow-mediated vasodilatation (FMD), in polycythaemia vera (PV) patients.
  • To determine if PV is associated with pre-clinical arterial disease, independent of established cardiovascular risk factors.

Main Methods:

  • High-resolution ultrasound was used to assess FMD and nitroglycerine-induced vasodilatation (NMD) in the brachial artery.
  • The study included 20 patients with PV and 20 age- and sex-matched healthy controls (CTL).

Related Experiment Videos

Main Results:

  • FMD was significantly impaired in PV patients compared to controls (7.6% vs. 11.6%, P=0.009).
  • NMD did not differ between PV patients and controls, suggesting preserved smooth muscle function.
  • Impaired FMD was independently associated with the presence of PV and vessel size, but not hematocrit or platelet count.

Conclusions:

  • Polycythaemia vera is linked to endothelial dysfunction in the early, pre-clinical stages of arterial disease.
  • The specific mechanisms driving this vascular reactivity alteration in PV require further investigation.